Live
- Reliance and Disney Complete JV Deal to Strengthen Entertainment Presence in India
- UP Govt Agrees to Protesters’ Demand, PCS Exam to Be Held in One Day
- Trump’s Social Security Tax Promise Faces Hurdles: What Retirees Need to Know
- Hyundai Motor India Limited Announces 2024 Edition of ‘Hyundai Always Around’ Campaign
- World Quality Day: Hindustan Zinc Reaffirms Commitment to Superior Product Quality & Innovation
- Samsung TV Plus Announces the Launch of Four New FAST Channels From Viacom18 Exclusively on Samsung Smart TVs
- Arun Pandey 3.0 set to revolutionise lottery industry with Great Goa Games (GGG)
- How Organisations Can Support Mobile Workforces with Diabetes - From Prevention to Management
- Google Rolls Out Real-Time Spam Detection Feature for Pixel Users
- Marriott international and Samhi hotels announce strategic expansion, sign agreement to open three more properties in india
India will now help protect children from pneumococcal disease
Pfizer today announced that its 13-valent Pneumococcal Conjugate Vaccine has been selected for inclusion in India’s immunization program in select states. In the first phase, the program will cover approximately 5.15 million babies – 20 per cent of around 26 million children of India’s birth cohort.
Pfizer today announced that its 13-valent Pneumococcal Conjugate Vaccine has been selected for inclusion in India’s immunization program in select states. In the first phase, the program will cover approximately 5.15 million babies 20 per cent of around 26 million children of India’s birth cohort.
Globally, pneumococcal disease is one of the leading causes of deaths in children younger than 5 years of age. In India, according to the Farooqui article published in 2015, approximately 105,000 children had died of pneumococcal pneumonia in 2010.
The 13-valent Pneumococcal Conjugate Vaccine (PCV 13) is the most widely used pneumococcal conjugate vaccine in the world, with deployment in over 100 countries’ immunization program. PCV 13 vaccine provides the broadest serotype coverage including those serotypes most prevalent in India.
Epidemiological studies conducted in India confirm that the PCV 13 vaccine provides higher coverage than any other PCV vaccine. The additional strains that PCV 13 covers are 3, 6A and 19A. PCV 13 will be introduced in a multi dose vial format in India. This presentation has been specially developed by Pfizer to enhance efficiencies of public immunization programs.
“The Government of India has made reaching every child with vaccines as a key priority. With the introduction of PCV 13, we will able to help protect India’s birth cohort of 26 million children from the leading cause of child deaths in the country. Pfizer remains committed to supporting the Government and its partners in expanding the introduction of PCV 13 in the country such that every child in India gets access to protection from pneumococcal diseases”, said S Sridhar, Country Manager, Pfizer India.
For the first phase of expansion, the vaccine will be supplied directly by Pfizer Inc. through UNICEF, under the auspices of Gavi, the Vaccine Alliance’s Advance Market Commitment an innovative funding mechanism that provides Gavi eligible and Gavi graduated countries with access to advanced life-saving vaccines.
